Sectoral Asset Management Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 64.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 27,150 shares of the biopharmaceutical company’s stock after selling 50,000 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Pfizer were worth $676,000 as of its most recent filing with the SEC.
Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank lifted its holdings in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its holdings in Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
- Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
- Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
- Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
- Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
- Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
- Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on PFE shares. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Finally, Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.61.
Check Out Our Latest Research Report on PFE
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
